Core Insights - The U.S. box office has seen a significant increase of over 25% compared to the same period last year, contributing to Marcus Theatres achieving its second-best pre-Christmas weekend since 2021 [1][2]. Company Performance - Marcus Theatres is experiencing a successful holiday season, driven by the release of highly anticipated films such as Avatar: Fire and Ash, which is expected to attract audiences throughout the holiday season and into 2026 [3]. - The company has recorded a record Memorial Day weekend earlier this year and continues to offer a diverse slate of films that appeal to various demographics [2]. Upcoming Releases and Events - Christmas Day is projected to be one of the busiest moviegoing days, with new films like Anaconda, Marty Supreme, and Song Sung Blue set to debut on December 25 [5]. - Marcus Theatres will also screen the finale of the popular TV show Stranger Things at select locations on December 31 and January 1 [6]. Promotions and Collectibles - The company is offering limited-time collectibles and giveaways, including Anaconda collectible prints and special popcorn buckets, as well as scratch-off cards for moviegoers with various prizes [8]. Company Overview - Marcus Theatres operates 985 screens across 78 locations in 17 states, making it the fourth-largest theatre circuit in the United States [9]. - The parent company, Marcus Corporation, is a leader in the lodging and entertainment industries, managing 16 hotels and resorts in addition to its theatre operations [10].

Core Viewpoint - TomaGold Corporation has amended its mineral property option agreement with SOQUEM Inc., affecting several properties including David, Radar, Dufault, Williams, Brosman, McKenzie, and Bruneau [1] Group 1 - The amendment to the agreement was made on August 11, 2023 [1] - The anniversary date for Year has been adjusted as part of the amendment [1]

Core Insights - The animated musical "David" by Angel is experiencing strong early domestic pre-sales, nearing $6 million, surpassing previous releases [1][2] - The film is set for a broad international release across 43 markets, reflecting high exhibitor confidence and a universal story theme [2][3] Company Overview - Angel (NYSE: ANGX) is a media and technology company supported by 1.6 million grassroots Angel Guild members who advocate for values-driven storytelling [1][9] - The company has a history of successful releases, including "Sound of Freedom," which grossed over $250 million globally [9] Film Details - "David" features a narrative centered on courage, faith, and hope, following the biblical story of David and Goliath [5] - The film is directed by Phil Cunningham and Brent Dawes, with music composed by Joseph Trapanese [6] Release Schedule - The U.S. release is scheduled for December 19, 2025, with international markets including Australia, New Zealand, and several Latin American countries following shortly after [3][7][11] Market Reception - Exhibitors express confidence in the film's potential, citing Angel's track record of delivering inspiring and high-quality films [4] - The film's themes resonate universally, appealing to diverse audiences across different regions [2][4] Upcoming Projects - Angel's future slate includes various genres, such as "I Was A Stranger," "Solo Mio," and "Young Washington," indicating a commitment to diverse storytelling [8]

Core Insights - Tempus AI's third-quarter 2025 results indicate a significant growth in its Insights and Data & Services business, which is becoming a high-margin revenue stream beyond traditional genomic testing [1][8] - Data and Services revenues reached $81.3 million, reflecting a 26.1% year-over-year increase, primarily driven by Insights (data licensing) [1][8] Business Performance - Insights bookings amounted to $150 million, showcasing a 37.6% year-over-year revenue growth, supported by a substantial foundation model deal signed earlier this year [2] - The company is effectively monetizing its extensive multimodal dataset, which includes genomic, clinical, imaging, and digital pathology information, alongside AI-powered insights and algorithms [2] Strategic Developments - Tempus enhanced its data and AI capabilities through the acquisition of Paige, a leader in digital pathology, which improves its dataset and technical expertise [3] - The collaboration with Northwestern Medicine has been expanded to integrate David, Tempus' generative AI clinical co-pilot, into the EHR platform, aiming to streamline clinical workflows [3] - Tempus Next has broadened its focus into breast cancer, providing real-time insights to assist clinicians in closing guideline-based care gaps [3] Market Position - Tempus is transitioning from a diagnostics-focused company to a differentiated data-driven precision medicine platform, with increasing potential for recurring revenue [4] - Over the past year, Tempus shares have increased by 10%, outperforming the industry, which saw a 4.1% decline [7] Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 8.18X, compared to the industry average of 5.81X, indicating a relatively expensive valuation [9]

Group 1 - Tempus AI Inc. is considered one of the least favorable AI stocks to invest in according to financial media [1] - An expanded collaboration between Northwestern Medicine and Tempus AI was announced, marking Northwestern Medicine as the first health system to integrate Tempus' generative AI-enabled clinical assistant, David, into its electronic health record (EHR) platform [1][2] - The partnership aims to enhance patient care by utilizing data and AI, building on a decade-long collaboration [2] Group 2 - The integration of David will provide Northwestern Medicine's clinical teams with real-time AI-enabled insights directly within the EHR [2][3] - By adopting Tempus' AI infrastructure, Northwestern Medicine will support its AI applications with a multimodal patient record, facilitating the co-development and real-time monitoring of new AI algorithms [3] - Clinical teams will be able to perform various functions, including building custom AI agents, querying patient data using natural language, and automating pre-appointment preparations with AI-generated summaries [3] Group 3 - Tempus AI Inc. specializes in healthcare technology, offering next-gen sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other pathology testing [4] - While there is potential for investment in Tempus AI, other AI stocks are viewed as having greater upside potential and lower downside risk [5]

Financial Data and Key Metrics Changes - The company reported total organic net sales down 3.5% in Q1, with an estimated 2.6% decline excluding the impact of the Hebrew National manufacturing disruption [26][28] - Adjusted operating margin declined 244 basis points year-over-year to 14.2% due to increased cost of goods sold inflation and higher merchandising investments [30][32] - Adjusted EPS was $0.53, down from $0.66 a year ago, primarily due to lower adjusted operating profit and unfavorable foreign exchange rates [32] Business Line Data and Key Metrics Changes - Grocery and Snacks segment delivered organic net sales of approximately $1.2 billion, a decline of 1.9% year-over-year, primarily from lower volumes [26] - Refrigerated and Frozen segment net sales were approximately $1.1 billion, down 5.7% from the prior year, significantly impacted by the Hebrew National disruption [27] - The International segment saw a 3% increase in organic net sales, driven by strong performance in global exports [28] Market Data and Key Metrics Changes - The company maintained a strong share performance, with approximately 71% of the portfolio holding or gaining volume share, outperforming peers [11][12] - In the frozen and snack domains, 93% of brands held or gained volume share during the quarter, indicating effective consumer engagement strategies [12][19] - The overall promotional environment remains rational, with Conagra operating with lower promotional volume compared to peers [13][14] Company Strategy and Development Direction - The company is focused on a value over volume strategy, particularly in foodservice, to sustain margins at pre-COVID levels [6][20] - Active portfolio reshaping initiatives were resumed, including the acquisition of Fatty Smoked Meat Sticks and divestiture of the Indian joint venture [7][23] - The company aims to achieve $1 billion in cost savings by the end of fiscal 2025 through productivity initiatives [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving fiscal 2025 goals despite challenges in the consumer environment [5][24] - The company anticipates sequential volume recovery each quarter and expects adjusted operating margin improvement in the second half of the fiscal year [35] - Inflationary pressures are expected to be around 3.2% for total cost of goods sold, with specific increases in proteins and sweeteners [36] Other Important Information - The company generated $269 million in net cash flows from operating activities in Q1, with capital expenditures of $133 million and dividends paid of $167 million [33][34] - Net leverage at the end of the quarter was 3.6 times, with a target of approximately 3.2 times by year-end [34] Q&A Session Summary Question: What were the impacts of the Hebrew National disruption on sales? - The disruption resulted in a 47% decline in revenue for the Hebrew National brand, equating to a 60 basis point reduction in total volume and a 90 basis point reduction in total organic net sales [7][8] Question: How is the company addressing inflationary pressures? - The company expects inflation of approximately 3.2% for total cost of goods sold, with specific pressures in proteins and sweeteners, but does not anticipate material impacts on margins or adjusted EPS from recent M&A transactions [36][37]